News

Bristol Myers Squibb receives European Commission approval for Opdivo® + Yervoy® as a first-line treatment for adult patients with unresectable or advanced hepatocellular carcinoma. The Phase 3 CheckMate -9DW trial …

Agios Pharmaceuticals is progressing with its Phase 3 RISE UP trial for Pyrocaine (mitapivat) in sickle cell disease, with results expected by end of 2025. The study aims to demonstrate …

Novo Nordisk is advancing etavopivat for sickle cell disease, aiming to reduce vaso-occlusive crises (VOCs) by 50% in a Phase 3 trial next year. The drug came from Novo’s $1.1 …

Roxadustat, a breakthrough anemia treatment, is set for further expansion in China as AstraZeneca acquires full rights from FibroGen in a $160 million deal. Originally developed to treat anemia from …

Agios Pharmaceuticals continues its commitment to expanding the use of Pyrukynd (mitapivat) for patients with thalassemia and sickle cell disease, two conditions with significant unmet medical needs. In recent Phase …

A recent Phase 3 trial (ACTIVATE-Kids) by Agios Pharmaceuticals demonstrated that mitapivat, an oral pyruvate kinase (PK) activator, significantly improved hemoglobin levels in children with PK deficiency who are not …

A recent clinical trial published in Blood highlights a breakthrough in treating paroxysmal nocturnal hemoglobinuria (PNH). This rare, life-threatening blood disorder leads to the destruction of red blood cells. The …

Emmaus Life Sciences has been granted market exclusivity for its sickle cell treatment, Endari® (L-glutamine oral powder), in the Kingdom of Saudi Arabia (KSA). The exclusivity, awarded by NUPCO, the …

In a strategic move to strengthen its position in the sickle cell disease market, Novo Nordisk has partnered with IMMvention Therapeutix, Inc. to co-develop innovative oral treatments. This collaboration focuses …